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Abstract
Background: One in three colon cancers are diagnosed as an emergency, which is associated with worse cancer
outcomes. Chronic conditions (comorbidities) affect large proportions of adults and they might influence the risk of
emergency presentations (EP).
Methods: We aimed to evaluate the effect of specific pre-existing comorbidities on the risk of colon cancer being
diagnosed following an EP rather than through non-emergency routes. The cohort study included 5745 colon
cancer patients diagnosed in England 2005–2010, with individually-linked cancer registry, primary and secondary
care data. In addition to multivariable analyses we also used potential-outcomes methods.
Results: Colon cancer patients with comorbidities consulted their GP more frequently with cancer symptoms
during the pre-diagnostic year, compared with non-comorbid cancer patients. EP occurred more frequently in
patients with ‘serious’ or complex comorbidities (diabetes, cardiac and respiratory diseases) diagnosed/treated in
hospital during the years pre-cancer diagnosis (43% EP in comorbid versus 27% in non-comorbid individuals;
multivariable analysis Odds Ratio (OR), controlling for socio-demographic factors and symptoms: men OR = 2.40;
95% CI 2.0–2.9 and women OR = 1.98; 95% CI 1.6–2.4. Among women younger than 60, gynaecological (OR = 3.41;
95% CI 1.2–9.9) or recent onset gastro-intestinal conditions (OR = 2.84; 95% CI 1.1–7.7) increased the risk of EP. In
contrast, primary care visits for hypertension monitoring decreased EPs for both genders.
Conclusions: Patients with comorbidities have a greater risk of being diagnosed with cancer as an emergency,
although they consult more frequently with cancer symptoms during the year pre-cancer diagnosis. This suggests
that comorbidities may interfere with diagnostic reasoning or investigations due to ‘competing demands’ or
because they provide ‘alternative explanations’. In contrast, the management of chronic risk factors such as
hypertension may offer opportunities for earlier diagnosis. Interventions are needed to support the diagnostic
process in comorbid patients. Appropriate guidelines and diagnostic services to support the evaluation of new or
changing symptoms in comorbid patients may be useful.
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Background
According to international data, emergency diagnoses
occur in up to 33% of colorectal cancers [1], with a higher
risk for colon (31%) than rectal cancers (15%) [2]. Redu-
cing emergency presentations is an important public
health target [3], as they are associated with poor cancer
survival, independently of stage at diagnosis [1], worse pa-
tient experience [4] and disruptions to hospital services
[5]. One-year survival is 49% after emergency diagnosis of
colorectal cancer compared to more than 80% for
non-emergency routes [6]. Although some emergency
diagnoses may be unavoidable, for example in rapidly pro-
gressing cancers with minimal or no prodromal symptoms
until an acute presentation [1, 7], in a large proportion of
cases emergency presenters have consulted their doctor
with relevant symptoms during the months before the
emergency cancer diagnosis [8–12]. Socio-economically
deprived individuals, women, the youngest and oldest
age-groups have increased risk of emergency presentations
[1, 2, 8, 13], but population-based evidence on why such
inequalities occur and how to reduce them is scant. Less
frequent help-seeking for cancer symptoms and diagnostic
delays due to atypical presentations are possible contribut-
ing factors.
Chronic conditions (hereafter called comorbidities)
affect more than 50% of older adults [14–16]. Comor-
bidities might confer a higher risk of emergency cancer
diagnosis [1], but current evidence is limited and mostly
relates to studies evaluating the overall presence and
number of comorbidities, without consideration of mor-
bidity type and potential effect modification by present-
ing symptom and socio-demographic characteristics.
Comorbidities providing ‘alternative’ explanations and
those interfering with the cancer diagnosis through
‘competing demands’ (being unrelated to cancer but
competing for clinical attention) can be associated with
longer diagnostic intervals [17], but their specific effects
on emergency presentations is unknown. Some comor-
bidities requiring regular follow-up visits might offer op-
portunities for earlier diagnosis [18].
In this study, using linked cancer registry, primary and
secondary care data with clinical information for up to 10
years pre-cancer [8], we aimed to provide population-based
evidence on the effect of specific comorbidities on primary
care consultations for cancer-related symptoms during the
year before a colon cancer diagnosis. We also aimed to esti-
mate the effect of specific comorbidities on the risk of can-
cer being diagnosed through emergency rather than
non-emergency routes, accounting for socio-demographic
factors and symptoms.
When using observational data for estimating average ef-
fects in the population, traditional epidemiological methods
can lead to biased results due to non-comparability of ex-
amined groups. Potential-outcomes or counterfactual
approaches can overcome this limitation. Such approaches
allowing to emulate randomized studies using observational
data [19–21] are increasingly used for estimating treatment
effects. They are also valuable for primary care and public
health research [22]. When examining complex factors, for
which many possible interventions exist, it is challenging to
estimate causal effects [23] and in such circumstances
potential-outcomes are particularly useful to clarify the
relevance of the issue under examination [24–26] and crit-
ically consider the complex relationships between expo-
sures and outcomes.
Thus, in addition to using conventional methods, we
aimed to employ potential-outcomes approaches for de-
termining the effects of specific comorbidities on the
risk of cancer being diagnosed through emergency rather
than non-emergency routes.
Methods
Study population and data sources
We included colon cancers (ICD-10 C18, further classi-
fied into distal C18.5-C18.7 and proximal C18.0-C18.4
[27–29] tumours) diagnosed in England 2005–2010 re-
corded in the Cancer Registry and linked to primary care
(Clinical Practice Research Datalink-CPRD) and second-
ary care data (Hospital Episode Statistics-HES). CPRD
provides prospectively collected patient-level informa-
tion on diagnoses, signs/symptoms and tests. Study in-
clusion criteria were: ages 18 years or over at cancer
diagnosis, no previous cancer, minimum 1 year of CPRD
records pre-cancer, meeting CPRD quality criteria.
CPRD covers 6.9% of the UK population and is repre-
sentative of the general population [30], and as expected
by the proportion of national coverage, 6.5% of all inci-
dent colon cancers registered in England during the
study period were linked to active and up-to-standard
CPRD records (N = 6316 out of 97,937 colon cancers di-
agnosed 2005–2010). After excluding patients with miss-
ing socio-demographic or route to diagnosis, N = 5745
individuals were included. Further details are reported
elsewhere [8, 31].
Study variables
The study outcome was emergency cancer diagnosis, defined
according to the Routes to Diagnosis algorithm, i.e. diagnosis
following presentation to Accident and Emergency, GP
emergency referrals, or emergency pathways for in/out-
patients [6, 32]. Non-emergency diagnoses included routine
GP referrals, two-week wait referral, inpatient/outpatient
elective and screening.
The main explanatory variables were comorbidities re-
corded before the diagnosis of cancer. Referring to the
literature [17] and clinical experts we compiled a list of
comorbidities potentially influencing the colon cancer
diagnosis through different mechanisms: 1) ‘serious’ or
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complex comorbidities diagnosed/treated in secondary
care, which can interfere with the cancer diagnosis
through competing demands: e.g. cardiac, chronic re-
spiratory, neurological diseases; 2) comorbidities possibly
providing alternative explanations for signs/symptoms of
cancer: gastrointestinal (GI) conditions (irritable bowel
syndrome (IBS), diverticular, coeliac, inflammatory
bowel, other GI diseases), gynaecological conditions
(endometriosis, dysmenorrhoea), anxiety/depression; 3)
comorbidities potentially offering opportunities for earl-
ier diagnosis through regular GP visits: hypertension
monitoring. Some comorbidities might act through mul-
tiple mechanisms: e.g. anxiety/depression, gynaecological
conditions or inflammatory bowel diseases might pro-
vide alternative explanations for cancer symptoms (ab-
dominal pain, diarrhoea, constipation), and also interfere
with the ability to focus on cancer symptoms through
competing demands.
‘Serious’ or complex comorbidities (see ‘1’ above) were
defined using relevant ICD-10- diagnosis codes in hospital
care records (Hospital Episodes Statistics-HES) [33, 34]
relating to hospital care episodes during a two-year period
before the cancer diagnosis. As linked HES records were
available from 2003 onwards, a two-year pre-diagnostic
window was chosen allowing the same HES observation
period for all patients. We also created a binary variable
coded as one if any HES record of ‘serious’ non-GI co-
morbidity versus none, excluding GI-conditions to focus
on the competing demand mechanism.
Comorbidities possibly providing alternative explana-
tions and those offering opportunities for earlier diagnosis
(see ‘2’ and ‘3’ above) were defined using relevant Med-
codes/Readcodes in CPRD relating to consultations for up
to 10-years before the diagnosis of cancer. Comorbidities
possibly presenting with abdominal symptoms (GI and gy-
naecological conditions), thus providing alternative expla-
nations, were categorized as ‘new onset’ (if first recorded
in the pre-diagnostic year) and ‘chronic/past’ (if already re-
corded 2–10 years pre-cancer). We hypothesised that ‘new
onset’ comorbidities might include mis-diagnoses (where
cancer symptoms were mis-interpreted as benign condi-
tions), rather than true comorbidities (chronic conditions
not related to cancer). Due to sparse data, IBS and diver-
ticular disease were grouped together.
Further explanatory variables were pre-diagnostic
alarm symptoms/signs (rectal bleeding, change in bowel
habit, anaemia) and other abdominal symptoms (e.g. ab-
dominal pain, constipation, diarrhoea) [10, 35, 36]. As
previously described [8] Medcodes/Readcodes for symp-
toms were applied to CPRD records in the 10 years
pre-diagnosis. Socio-demographic characteristics in-
cluded gender, age and deprivation (Index of Multiple
Deprivation for England). Cancer sub-sites were classi-
fied into distal (left) colon (i.e. splenic flexure,
descending colon, sigmoid colon) (ICD C18.5-C18.7)
and proximal (right) colon (i.e. caecum, appendix, as-
cending colon, hepatic flexure, transverse) (C18.0-C18.4)
[27–29].
Statistical analysis
We compared comorbidities, signs/symptoms and socio-
demographic characteristics among emergency versus
non-emergency presenters. We examined whether consult-
ation rates for cancer symptoms during the pre-diagnostic
year varied by specific comorbidities, controlling for
socio-demographic factors, using negative binomial regres-
sion. The Pearson goodness-of-fit and likelihood ratio tests
comparing negative binomial with Poisson regression
models, indicated that negative binomial regression was
more appropriate due to over-dispersion.
We evaluated the proportion of emergency presenters
with alarm symptoms recorded in the pre-diagnostic
year by comorbidity status, to evaluate if opportunities
for earlier diagnosis vary by comorbidity type. Using
multivariable logistic regression we examined the risk of
emergency presentations for different comorbidities,
controlling for socio-demographic characteristics, GP
consultations and signs/symptoms, cancer sub-site and
year of cancer diagnosis. Random effects accounted for
possible patient clustering by practice. Men and women
were examined separately and we assessed effect modifi-
cation by age. In line with previous research on colon
cancer [37], we decided a priori to examine men and
women separately, considering that comorbidities differ
in men and women and their impact on emergency pre-
sentations might be modified by gender. In particular,
gynaecological conditions only affect women and other
chronic conditions, such as Irritable Bowel Syndrome
(IBS), affect women much more frequently than men
[38, 39]. Tumour factors also differ by gender: proximal
cancers, which often present with non-specific symp-
toms and are beyond the reach of flexible sigmoidoscopy
[40], occur more frequently in women, possibly leading
to gender differences in diagnostic complexity.
Finally, in addition to using the traditional epidemio-
logical methods described above, we analysed the same data
also using potential-outcomes or counterfactual-based
approaches, estimating the effects of comorbidities on
the risk of cancer being diagnosed through emergency
rather than non-emergency routes in the population
of colon cancer patients. We considered that covari-
ates (socio-demographic factors and symptoms) might
have differential effects on the exposure (comorbidity)
and also affect the outcome (emergency presentations)
(see Additional file 1 for a graphic representation and
methodological details).
Statistical analyses were performed using STATA14
(Stata Corp., College Station, TX, USA).
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Results
Comorbidities recorded prior to cancer diagnosis among
emergency or non-emergency presenters
Among the 5745 colon cancer patients, 34% of
women and 30% of men were diagnosed as emergen-
cies. Overall, emergency cancer diagnosis occurred in
43% of patients with pre-existing ‘serious’ non-GI
comorbidity versus 27% in individuals without comor-
bidity (p < 0.001). Examining specific pre-existing ‘ser-
ious’ comorbidities has shown that almost all of them
were more prevalent in emergency than non-emer-
gency presenters (Table 1).
Primary care comorbidities were similar in emergency
and non-emergency presenters, except for a higher fre-
quency among non-emergency presenters of haemor-
rhoids in women and hypertension monitoring in both
genders (Table 1). The most frequent primary care co-
morbidities were anxiety/depression and IBS/diverticular
disease. IBS/diverticular diseases showed a stable preva-
lence 2–5 years pre-cancer (women: 1.4 to 2.3%; men:
0.5 to 1%), with a marked increase in the pre-diagnostic
year (women: 6.2%; men: 3.5%) (data not shown).
Consultations with potential cancer symptoms among
comorbid and non-comorbid patients
Consultation rates with potential cancer symptoms over
the 5-years pre-diagnosis were stable up to the
pre-diagnostic year, when a marked increase was ob-
served for emergency and non-emergency presenters.
However, among female emergency presenters with ‘ser-
ious’ non-GI comorbidities diagnosed/treated in second-
ary care, GP consultations with potential cancer
symptoms started increasing 2 years pre-diagnosis
(Fig. 1). Comorbid individuals consulted more frequently
with cancer symptoms during the pre-diagnostic year
than non-comorbid individuals, controlling for
socio-demographic factors and cancer sub-site (Fig. 2).
Among emergency presenters, the proportion of patients
with cancer alarm symptoms (rectal bleeding, anaemia,
change in bowel habit) recorded in primary care in the
pre-diagnostic year (i.e. indicating possible missed diag-
nostic opportunities) was 21% among men with ‘serious’
hospital-treated comorbidities versus 11% among
non-comorbid men (p < 0.001) (Table in Additional file 2).
Patients with anxiety/depression also more frequently
had alarm symptoms recorded the year before emer-
gency cancer diagnosis compared to those never hav-
ing had anxiety/depression (women: 36% versus 18%
(p = 0.002); men 22% versus 13% (p = 0.021). Simi-
larly, female emergency presenters with IBS/diverticu-
lar disease had more frequent records of alarm
symptoms in the year pre-cancer diagnosis compared
to those never having had IBS/diverticular disease
(32% versus 19%; p = 0.008).
Multivariable analysis examining the effect of
comorbidities on emergency presentations
Men and women with pre-existing ‘serious’ non-GI comor-
bidities diagnosed/treated in secondary care had a signifi-
cantly higher risk of emergency presentations, controlling
for socio-demographic factors and symptoms (Fig. 3). In
contrast, hypertension monitoring decreased the risk of
emergency presentation. Among women, gynaecological
and IBS/diverticular diseases increased the risk of emer-
gency presentations. New onset alarm symptoms decreased
emergency presentations for both genders.
Examining the effects of comorbidities stratified by age
and controlling for deprivation, cancer sub-site and
symptoms, showed how the risk of emergency presenta-
tion was particularly high for women aged less than 60
with gynaecological conditions (OR = 3.41; 95%CI 1.2–
9.9) and for those with recent IBS/diverticular disease
diagnoses (OR = 2.84; 95%CI 1.2–7.7) (Table 2). The risk
was also higher for women aged 70–79 with gynaeco-
logical or ‘serious’ non-GI comorbidities, and for women
aged 80 or more with a past history of IBS/diverticular
disease or ‘serious’ non-GI comorbidities. For men,
age-stratified results (data not shown) were similar to
those for all age-groups combined shown in Fig. 3.
Potential-outcomes approach estimating the average effect
of comorbidities on emergency presentations
The findings obtained through standard multivariable
analysis were corroborated using potential-outcomes
methods (Table 3). Overall, at population level, the risk
of emergency presentation for both genders was in-
creased by ‘serious’ non-GI comorbidities. Age-stratified
analyses showed a particularly high average risk for some
subgroups of colon cancer patients, such as women aged
less than 60 with a recent IBS/diverticular disease or be-
nign gynaecological diagnosis, and women aged 80 or
more with a past history of IBS/diverticular disease. All
estimates accounted for socio-demographic characteris-
tics, cancer symptoms and other comorbidities. In par-
ticular, Table 3 shows the potential outcome mean
(POmean), which corresponds to the proportion of
emergency cancer diagnoses we would expect among
colon cancer patients if nobody had the examined co-
morbidity. After estimating the potential outcome mean
we would expect if everybody had that comorbidity, we
calculated the difference between the two means (risk
difference or average treatment effect, ATE). The ATE
corresponds to the average effect of each comorbidity on
the risk of emergency presentations. For example, exam-
ining the effect of ‘serious’ non-GI comorbidities (re-
corded in HES) we obtained a POmean = 0.30 for
women and POmean = 0.25 for men, indicating that in
the absence of ‘serious’ non-GI comorbidities, 30% of
women with colon cancer and 25% of men can be
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Table 1 Socio-demographic characteristics, comorbidities and cancer alarm symptoms among individuals diagnosed with colon
cancer following emergency (EP) and Non-emergency presentation (non-EP)
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expected to have an emergency presentation. An ATE =
0.12 for women and ATE = 0.15 for men indicate that
the presence of a ‘serious’ comorbidity would significantly
increase these proportions (p < 0.001), adding a further
12 and 15% of emergency presentations among women
and men, respectively. Overall, this would result in 42%
of comorbid women with colon cancer and 40% of co-
morbid men having an emergency presentation. Signifi-
cant effects were also found for COPD, diabetes and
cardiac disease.
In contrast, hypertension monitoring in primary care
during the pre-diagnostic year had an average protective
effect, albeit small, in women and men (ATE = -9% and
ATE = -4%). The other comorbidities recorded in
primary care had no significant effect when analysing all
age-groups together.
Age-stratified analyses have shown that if women aged
less than 60 never have a diagnosis of IBS/diverticular
disease, the average risk of emergency presentation can
be expected to be 35%. New onset IBS significantly in-
creased emergency presentations (ATE = 22%), while
chronic/past IBS decreased the risk (ATE = -29%). Thus,
the overall risk of emergency presentations for women
aged less than 60 with colon cancer and new onset IBS/
diverticular disease would be 57%, while it would be 6%
for those with a chronic/past IBS. Gynaecological condi-
tions also significantly increased the risk for women
aged less than 60. Among women aged 80 or more the
Fig. 1 Consultation rates in primary care for cancer symptoms pre-diagnosis for emergency (EP) and non-emergency presenters (non-EP) with
and without hospital-treated comorbidities. Observed data points and fitted local polynomial regression lines
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risk of emergency diagnosis was also significantly in-
creased by COPD or cardiac diseases or a past history of
IBS/diverticular disease.
Findings for men did not differ by age-group (data not
shown) and thus age-stratified results are only reported
for women in Table 3.
Discussion
Summary
Most comorbidities increased the risk of emergency colon
cancer diagnosis, but the effects are complex and vary by
socio-demographic factors and by type and timing of co-
morbidity onset. Comorbid patients consulted more
frequently with cancer symptoms than non-comorbid in-
dividuals in the pre-diagnostic year and some comorbidi-
ties offered opportunities for earlier diagnosis. The risk of
emergency presentations was particularly high for some
subgroups, including patients with ‘serious’ comorbidities
diagnosed/treated in secondary care (diabetes, cardiac, re-
spiratory diseases) and women aged less than 60 with a re-
cent diagnosis of IBS/diverticular disease or benign
gynaecological conditions. One-fifth of emergency pre-
senters with ‘serious’ comorbidities, diagnosed/treated in
secondary care, presented with cancer alarm symptoms in
primary care during the pre-diagnostic year, suggesting
opportunities for reducing emergency presentations. One
Fig. 2 Incidence Rate Ratios (IRR) for primary care consultations with relevant symptoms during the pre-diagnostic year. Negative binomial
regression including in the model all the variables shown in the figure, as well as cancer sub-site. SES=Socio-economic status; New onset
comorbidity = comorbidity first recorded during the year pre-cancer diagnosis; Chronic/past = already recorded > 12 months pre-cancer diagnosis;
Hypertension monitoring between 30 days and 12 months pre-cancer diagnosis
Renzi et al. BMC Health Services Research          (2019) 19:311 Page 7 of 14
in three female emergency presenters with a recent diag-
nosis of IBS/diverticular disease consulted their GP with
cancer alarm symptoms in the year pre-cancer diagnosis.
Traditional epidemiological methods and counterfac-
tual-based approaches yielded similar findings.
Strengths and limitations
A detailed examination of specific comorbidities prospect-
ively recorded in primary and secondary care allowed us to
substantially add to the literature, highlighting how comor-
bidities can influence the risk of emergency presentations,
acting through different mechanisms, with patients’ gender
and age modifying their effect. It is the first
population-based study, using high-quality primary and
secondary care data linked to cancer registration and routes
to diagnosis data, showing contrasting effects of different
comorbidities on emergency presentations. By identifying
higher risk groups the study can help develop targeted
strategies for reducing emergency presentations. A substan-
tial proportion of emergency presenters had primary care
consultations with alarm symptoms during the pre-
diagnostic year, particularly among comorbid patients, sug-
gesting that there are opportunities for earlier diagnosis.
Sensitivity analyses changing the time-window for defining
Fig. 3 Likelihood of emergency colon cancer diagnosis: Mixed effects multivariable logistic regression Odds Ratios. Adjusted ORs from
multivariable regression analysis including in the model all the variables shown in the figure, as well as socio-demographic characteristics and
number of consultations in the pre-diagnostic year. New onset comorbidity = comorbidity first recorded during the year pre-cancer diagnosis;
Chronic/past = comorbidity already recorded > 12 months pre-cancer diagnosis; Hypertension monitoring between 30 days and 12months
pre-cancer diagnosis
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‘serious’ comorbidities diagnosed/treated in hospital (e.g. in-
cluding only comorbidities recorded more than 6 or 12
months pre-cancer) confirmed an increased risk of emer-
gency presentation for comorbid patients (data not shown).
Relying on routinely collected data we probably under-
estimated the prevalence of symptoms and comorbidities,
but this likely occurred in a non-differential way, as infor-
mation was prospectively recorded.
Linked data was only available for our analyses up to
2010. Emergency presentations for colorectal cancer
have decreased in England between 2006 and 2010 (from
27 to 24%), however no further reductions have been re-
ported since 2010 [2, 6]. Inequalities in emergency pre-
sentations [2] and poorer survival for cancer patients
diagnosed as an emergency [41] are persisting problems.
Similarly, in our study focusing specifically on colon
cancer, emergency presentations decreased between
2006 and 2010 (from 36 to 32% among women and from
33 to 29% among men), but year of diagnosis did not
modify the effect of comorbidities on emergency presen-
tations (data not shown).
Comparison with existing literature
The relationship between comorbidities and emergency pre-
sentations is complex, with multiple pathways possibly
leading to delays (influenced by biological, psychological and
organizational factors affecting patients and doctors) [1, 13,
42–45]. Recent research reported how ‘competing demands’
(for example, cardiac conditions) and ‘alternative explanation’
comorbidities (including IBS/diverticular diseases) are associ-
ated with longer diagnostic intervals [17], but their effects on
emergency presentations were unknown.
In contrast, some previous studies [18, 42] reported
how chronic ‘risk factor’ conditions, such as hyperten-
sion, which in themselves are typically asymptomatic,
can offer opportunities for patients to mention possible
cancer symptoms during regular healthcare encounters
or for doctors to notice new sign/symptoms, leading to
earlier cancer diagnosis, which is in line with our find-
ings. While such ‘risk factor’ conditions, monitored in
primary care, are usually not perceived as particularly
worrying, this is not the case for ‘competing demands’
comorbidities, such as cardiac conditions or complicated
diabetes treated in secondary care. ‘Competing demands’
comorbidities are frequently ‘serious’/complex to man-
age or require urgent clinical attention- and critically
they can give rise to new symptoms. Thus, despite being
associated with frequent healthcare encounters, instead
of providing opportunities for earlier cancer diagnosis,
‘competing demands’ comorbidities are more likely to
interfere with timely investigations of possible cancer
Table 2 Age-stratified multivariable logistic regression Odds Ratios (OR) for the risk of emergency colon cancer diagnosis among
women
Renzi et al. BMC Health Services Research          (2019) 19:311 Page 9 of 14
Ta
b
le
3
Es
tim
at
ed
av
er
ag
e
ef
fe
ct
(A
TE
)
of
co
m
or
bi
di
tie
s
on
em
er
ge
nc
y
pr
es
en
ta
tio
ns
an
d
po
te
nt
ia
lo
ut
co
m
e
(P
O
)
m
ea
n,
ta
ki
ng
in
to
ac
co
un
t
so
ci
o-
de
m
og
ra
ph
ic
ch
ar
ac
te
ris
tic
s,
ot
he
r
co
m
or
bi
di
tie
s
an
d
ca
nc
er
al
ar
m
sy
m
pt
om
s
Renzi et al. BMC Health Services Research          (2019) 19:311 Page 10 of 14
symptoms, particularly if symptoms are vague [44, 46,
47], increasing the risk of emergency presentations.
Other chronic conditions, such as IBS or diverticular
disease, can lead to delays by providing alternative expla-
nations, influencing patients’ help-seeking for possible
cancer symptoms and/or referrals for investigations.
Sparse data limited the possibility of analysing IBS and
diverticular diseases separately in our study. However, as
IBS and diverticular diseases have many overlapping
clinical features and often present with recurrent ab-
dominal symptoms [48], they can both complicate differ-
ential diagnosis with cancer [49]. A Dutch study [50]
reported how sometimes doctors attribute colorectal
cancer symptoms to pre-existing conditions in patients
with a history of diverticulitis or gynaecological condi-
tions. Similarly, the higher risk of emergency cancer
diagnosis among women aged less than 60 with a recent
diagnosis of IBS/diverticular disease or benign gynaeco-
logical conditions highlighted in our study, can be ex-
plained at least in part by a mis-attribution of cancer
symptoms to benign conditions. This is supported by
our findings showing a marked increase in IBS/diverticu-
lar disease records shortly before the cancer diagnosis.
The ‘baseline’ prevalence of IBS/diverticular disease 2–5
years pre-cancer in our sample was low and similar to
previous primary care studies (2.5%) [51, 52]. IBS preva-
lence in the general population varies widely [52], de-
pending on diagnostic criteria and data sources [39], but
what is noteworthy here is the increase during the
pre-diagnostic months. Some cases might have been
‘working’ diagnoses possibly followed by investigations,
nevertheless our study highlighted how a recent IBS
diagnosis can increase emergency presentations particu-
larly in women.
In contrast, long-standing IBS/diverticular diseases
had a protective effect in younger women, suggesting
that in these circumstances women and/or doctors rec-
ognized that symptoms had changed. Familiarity with
the healthcare system, more opportunities to discuss
symptoms with the doctor and tumour biology might
also have played a role, with some women with
long-standing symptoms possibly having slow-growing
and less aggressive cancers. Differently from younger
women, older women with a past history of IBS/diver-
ticular disease had an increased risk of emergency pre-
sentations. Advanced age might have prevented invasive
investigations due to patients’ health status, their prefer-
ences or barriers accessing healthcare [53].
Patients sometimes attribute cancer symptoms to comor-
bidities or delay reporting them due to worries about wasting
doctors’ time [45, 54]. We could not examine cancer aware-
ness or timely reporting of symptoms, however our study
highlighted how comorbid patients consulted significantly
more with cancer symptoms than non-comorbid individuals.
Thus, diagnostic delays cannot simply be explained by pa-
tients not seeing their doctor for cancer symptoms.
Implications for research and practice
One in three colon cancers are diagnosed as an emer-
gency, with higher risks for comorbid patients especially
if belonging to the youngest or oldest age-groups. Redu-
cing emergency cancer diagnosis is an important public
health target, given its negative consequences in terms
of survival, independently of stage [1, 3]. Appropriate in-
terventions are necessary for the large number of indi-
viduals with comorbidities who experience potential
cancer symptoms. Innovative diagnostic strategies need
to be developed targeting higher risk groups and taking
into account the specific mechanisms through which co-
morbidities might affect diagnostic timeliness. In par-
ticular, greater integration between primary and
secondary care, as well as more extensive use of
multi-disciplinary diagnostic centres, which are currently
being evaluated in different countries [55–57], can play
an important role for complex patients, such as those
with comorbidities. Sufficient consultation time is im-
portant especially for patients with multi-morbidities
and vague symptoms in order to adopt a holistic ap-
proach and reduce delays [58]. Optimization of health-
care services [59–61] and support from nurses could
help to free up consultation time. In addition to
system-wide approaches, targeted interventions are
needed. For example, colon cancer diagnosis in women
can be particularly complex because of gynaecological
conditions and the higher prevalence of IBS [38, 39],
highlighting the importance of safety-netting strategies
and innovative diagnostic approaches tailored for higher
risk groups. Recent research [62, 63] and NICE guide-
lines [36], indicate that quantitative faecal haemoglobin
testing (FIT) can be useful for patients presenting with
abdominal symptoms in primary care to identify those
who might benefit from further investigations. Moreover,
according to international experts, a colonoscopy is indi-
cated for patients aged 50 years and over with symptoms
such as diarrhoea and mixed bowel habit [64, 65]. Relat-
edly, the American Gastroenterology Association re-
cently recommended excluding colon cancer with
modern techniques and colonoscopy after the first epi-
sode of diverticulitis [49].
International evidence on emergency cancer diagno-
sis is scant, but what there is suggests that the prob-
lem is not limited to the UK [1], particularly for
cancers initially presenting with non-specific symp-
toms. More international data could provide insights
into the role played by healthcare factors in influen-
cing diagnostic timeliness. Patient’s healthcare records
can be a useful resource not only for reporting com-
posite comorbidity measures, such as the Charlson
Renzi et al. BMC Health Services Research          (2019) 19:311 Page 11 of 14
comorbidity index, but also to evaluate specific co-
morbidities. The importance of examining specific co-
morbidities is increasingly being recognised in the
international literature [44, 47, 66, 67]. A detailed
analysis of type and timing of comorbidities and spe-
cific pathways is necessary to better understand the
mechanisms leading to delays and identify appropriate in-
terventions. The effects of comorbidities are complex and
patient, doctors and healthcare system factors all need to
be considered in order to reduce their impact on emer-
gency presentations and improve cancer outcomes.
Conclusions
The study highlighted how most comorbidities increased
the risk of emergency colon cancer diagnosis, but the ef-
fects are complex and vary by socio-demographic factors
and by type of comorbidity. The risk of emergency pres-
entation was particularly high for some subgroups, in-
cluding patients with ‘serious’ comorbidities diagnosed/
treated in hospital during the years pre-cancer diagnosis
(diabetes, cardiac, respiratory diseases) and women aged
less than 60 with a recent diagnosis of IBS/diverticular
disease or benign gynaecological conditions. By identify-
ing higher risk groups the study can help develop tar-
geted strategies for reducing emergency presentations. A
substantial proportion of emergency presenters had pri-
mary care consultations with alarm symptoms during
the pre-diagnostic year, particularly among comorbid pa-
tients. This suggests that comorbidities may interfere
with diagnostic reasoning or investigations due to ‘com-
peting demands’ or because they provide ‘alternative ex-
planations’. In contrast, the management of chronic risk
factors such as hypertension may offer opportunities for
earlier diagnosis. Interventions are needed to support
the diagnostic process in comorbid patients. Appropriate
guidelines and diagnostic services to support the evalu-
ation of new or changing symptoms in comorbid pa-
tients may be useful.
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